TWINRIX™
ApprovedBiologic
GSKTWINRIX™ is one of 195 biologic programs targeting HIV infection. It is currently in Approved.
6
Indications
16
Total Trials
0
Active Trials
194
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
326 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Hivid
CConrado Roberto Hoffmann Filho
Phase 3
Praluent
RegeneronPhase 3
TWINRIX™
GSKApproved
Betaseron
BayerPhase 3
PEG-Intron
Merck & Co.Phase 3
Megace
Bristol-Myers SquibbPhase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Foscavir
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis8 trials
Show 5 more trials
Hepatitis B2 trials
Memory1 trial
Substance Abuse1 trial
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
Completed·—·Phase 2·NCT00316303·236 enrolled
Plasmodium falciparum malaria1 trial
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02334462·538 enrolled
3 more indications
HIV infection1 trial
Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2
Unknown status·—·Phase 3·NCT00451984·80 enrolled
Immunogenicity1 trial
Vaccines1 trial
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00393276·29 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TWINRIX™. EMBL-EBI & Wellcome Sanger Institute.
- [4]